← All trials
NCT06508983
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 14, 2024
- Primary completion
- Mar 31, 2027
- Completion date
- Mar 31, 2028
- First posted
- Jul 19, 2024
- Last posted
- Jul 23, 2024
- Enrollment
- 360
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Hangzhou Sumgen Biotech Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.